The Complementary Role of Imaging and Tumor Biomarkers In Gynecological Cancers: An Update of the Literature

Overview

Journal Asian Pac J Cancer Prev

Specialty Oncology

Date 2018 Feb 27

PMID 29479951

Citations 7

Authors

Emanuela Anastasi

Silvia Gigli

Laura Ballesio

Antonio Angeloni

Lucia Manganaro

Affiliations

Soon will be listed here.

Abstract

Gynecological tumors, including endometrial, cervical and ovarian cancer, have increased in incidence over time. The widespread introduction of screening programs and advances in diagnostic imaging methods has lead to a progressive increase in gynecological cancer detection. Accurate diagnosis and proper monitoring of disease remain the primary target for a successful treatment. In the last years, knowledge about cancer biomarkers has considerably increased providing great opportunities for improving cancer detection and treatment. In addition, in the last few years there has been an important development of imaging techniques. Nowadays, a multimodal approach including the evaluation of serum tumor biomarkers combined with imaging techniques, seems to be the best strategy for assessing tumor presence, spread, recurrence, and/or the response to treatment in female cancer patients In this review we provide an overview of the application of biomarkers combined with novel imaging methods and highlight their roles in female cancer diagnosis and follow-up.

Citing Articles

Promising predictive molecular biomarkers for cervical cancer (Review).

Lizano M, Carrillo-Garcia A, De La Cruz-Hernandez E, Castro-Munoz L, Contreras-Paredes A Int J Mol Med. 2024; 53(6).

PMID: 38606495 PMC: 11090266. DOI: 10.3892/ijmm.2024.5374.

Predicting Response to Chemotherapy in Patients With Newly Diagnosed High-Risk Neuroblastoma: A Report From the International Neuroblastoma Risk Group.

Mayampurath A, Ramesh S, Michael D, Liu L, Feinberg N, Granger M JCO Clin Cancer Inform. 2021; 5:1181-1188.

PMID: 34882497 PMC: 8812615. DOI: 10.1200/CCI.21.00103.

Clinical value of serum biomarkers, squamous cell carcinoma antigen and apolipoprotein C-II in follow-up of patients with locally advanced cervical squamous cell carcinoma treated with radiation: A multicenter prospective cohort study.

Harima Y, Ariga T, Kaneyasu Y, Ikushima H, Tokumaru S, Shimamoto S PLoS One. 2021; 16(11):e0259235.

PMID: 34727105 PMC: 8562853. DOI: 10.1371/journal.pone.0259235.

Success of I-Seed Treatment in Vulvar Squamous-Cell Carcinoma with Aplastic Anemia: A Case Report.

Ni Q, Pan C, Guo Q, Wang P, Sun G, Xiao S Onco Targets Ther. 2020; 13:12561-12566.

PMID: 33324074 PMC: 7733133. DOI: 10.2147/OTT.S283006.

Coordination of Nanoconjugation with an Antigen/Antibody for Efficient Detection of Gynecological Tumors.

Liu X, Yang X, Shao J, Hong Y, Gopinath S, Chen Y J Anal Methods Chem. 2020; 2020:6528572.

PMID: 32309010 PMC: 7149363. DOI: 10.1155/2020/6528572.

References

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M . Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014; 136(5):E359-86. DOI: 10.1002/ijc.29210. View

Haldorsen I, Salvesen H . Staging of endometrial carcinomas with MRI using traditional and novel MRI techniques. Clin Radiol. 2011; 67(1):2-12. DOI: 10.1016/j.crad.2011.02.018. View

Midulla C, Manganaro L, Longo F, Viggiani V, Frati L, Granato T . HE4 combined with MDCT imaging is a good marker in the evaluation of disease extension in advanced epithelial ovarian carcinoma. Tumour Biol. 2012; 33(5):1291-8. DOI: 10.1007/s13277-012-0376-5. View

Tilli T, Bellahcene A, Castronovo V, Gimba E . Changes in the transcriptional profile in response to overexpression of the osteopontin-c splice isoform in ovarian (OvCar-3) and prostate (PC-3) cancer cell lines. BMC Cancer. 2014; 14:433. PMC: 4075779. DOI: 10.1186/1471-2407-14-433. View

Alcazar J, Galvan R, Albela S, Martinez S, Pahisa J, Jurado M . Assessing myometrial infiltration by endometrial cancer: uterine virtual navigation with three-dimensional US. Radiology. 2009; 250(3):776-83. DOI: 10.1148/radiol.2503080877. View

Engelen M, Kos H, Willemse P, Aalders J, de Vries E, Schaapveld M . Surgery by consultant gynecologic oncologists improves survival in patients with ovarian carcinoma. Cancer. 2005; 106(3):589-98. DOI: 10.1002/cncr.21616. View

Granato T, Porpora M, Longo F, Angeloni A, Manganaro L, Anastasi E . HE4 in the differential diagnosis of ovarian masses. Clin Chim Acta. 2015; 446:147-55. DOI: 10.1016/j.cca.2015.03.047. View

Oza A, Elit L, Tsao M, Kamel-Reid S, Biagi J, Provencher D . Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group. J Clin Oncol. 2011; 29(24):3278-85. PMC: 3158598. DOI: 10.1200/JCO.2010.34.1578. View

Anastasi E, Gigli S, Santulli M, Tartaglione S, Ballesio L, Porpora M . Role of Galectin-3 Combined with Multi- Detector Contrast Enhanced Computed Tomography in Predicting Disease Recurrence in Patients with Ovarian Cancer. Asian Pac J Cancer Prev. 2017; 18(5):1277-1282. PMC: 5555535. DOI: 10.22034/APJCP.2017.18.5.1277. View

10.

Cohn D, Dehdashti F, Gibb R, Mutch D, Rader J, Siegel B . Prospective evaluation of positron emission tomography for the detection of groin node metastases from vulvar cancer. Gynecol Oncol. 2002; 85(1):179-84. DOI: 10.1006/gyno.2002.6605. View

11.

Walentowicz P, Krintus M, Sadlecki P, Grabiec M, Mankowska-Cyl A, Sokup A . Serum inhibin A and inhibin B levels in epithelial ovarian cancer patients. PLoS One. 2014; 9(3):e90575. PMC: 3944095. DOI: 10.1371/journal.pone.0090575. View

12.

Siegel C, Andreotti R, Cardenes H, Brown D, Gaffney D, Horowitz N . ACR Appropriateness Criteria® pretreatment planning of invasive cancer of the cervix. J Am Coll Radiol. 2012; 9(6):395-402. DOI: 10.1016/j.jacr.2012.02.021. View

13.

Liu B, Gao S, Li S . A Comprehensive Comparison of CT, MRI, Positron Emission Tomography or Positron Emission Tomography/CT, and Diffusion Weighted Imaging-MRI for Detecting the Lymph Nodes Metastases in Patients with Cervical Cancer: A Meta-Analysis Based on 67 Studies. Gynecol Obstet Invest. 2017; 82(3):209-222. DOI: 10.1159/000456006. View

14.

Bilici A, Ustaalioglu B, Seker M, Canpolat N, Tekinsoy B, Salepci T . Clinical value of FDG PET/CT in the diagnosis of suspected recurrent ovarian cancer: is there an impact of FDG PET/CT on patient management?. Eur J Nucl Med Mol Imaging. 2010; 37(7):1259-69. DOI: 10.1007/s00259-010-1416-2. View

15.

Ortoft G, Dueholm M, Mathiesen O, Hansen E, Lundorf E, Moller C . Preoperative staging of endometrial cancer using TVS, MRI, and hysteroscopy. Acta Obstet Gynecol Scand. 2013; 92(5):536-45. DOI: 10.1111/aogs.12103. View

16.

Land R, Herod J, Moskovic E, King M, Sohaib S, TROTT P . Routine computerized tomography scanning, groin ultrasound with or without fine needle aspiration cytology in the surgical management of primary squamous cell carcinoma of the vulva. Int J Gynecol Cancer. 2006; 16(1):312-7. DOI: 10.1111/j.1525-1438.2006.00340.x. View

17.

Freydanck M, Laubender R, Rack B, Schuhmacher L, Jeschke U, Scholz C . Two-marker combinations for preoperative discrimination of benign and malignant ovarian masses. Anticancer Res. 2012; 32(5):2003-8. View

18.

Spencer J, Ghattamaneni S . MR imaging of the sonographically indeterminate adnexal mass. Radiology. 2010; 256(3):677-94. DOI: 10.1148/radiol.10090397. View

19.

Lee S, Catalano O, Dehdashti F . Evaluation of gynecologic cancer with MR imaging, 18F-FDG PET/CT, and PET/MR imaging. J Nucl Med. 2015; 56(3):436-43. DOI: 10.2967/jnumed.114.145011. View

20.

Barton D . The prevention and management of treatment related morbidity in vulval cancer. Best Pract Res Clin Obstet Gynaecol. 2003; 17(4):683-701. DOI: 10.1016/s1521-6934(03)00045-2. View